EE687 The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.1068
https://www.valueinhealthjournal.com/article/S1098-3015(25)03625-3/fulltext
Title :
EE687 The Budget Impact and Time Savings of Introducing Subcutaneously Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenously Administered Nivolumab (NIVO IV) Across Indications in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03625-3&doi=10.1016/j.jval.2025.09.1068
First page :
Section Title :
Open access? :
No
Section Order :
10610